Sep 11, 2020

OnDosis announces commitment of 30 MSEK raise from existing owners and DIG Investment

Following the signing of a breakthrough agreement with a leading Business-to-Business Pharma company, OnDosis announces the commitment of a 30 MSEK raise from existing owners and DIG Investment.

Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines with digital therapeutics and intelligent dosing.

OnDosis selected to pitch at European Angel Investment Summit

This week, OnDosis is one of 40 startups who will get to pitch in front of investors from all over the world at European Angel Investment Summit in Brussels 25–26 November. In addition, we're participating at The 29th MedTech Investing Europe Conference in London 26–27 November. Read more: http://europeanangelsummit.com/startups/ http://www.medtechinvesting.com/

Nov 15, 2019

Major article on the opportunities with On Dosis in IPI Magazine

Pharmaceutical innovation is accelerating fast, but the way of dosing oral medicines to patients has very much stayed the same. This article in IPI magazine, “Beyond the Pill Personalisation by Integrating Oral Medication and Digitalisation”, highlights the opportunities with OnDosis.

OnDosis awarded Horizon 20/20 funding and attending key meetings to broaden partnerships

During the first half of 2019 OnDosis was awarded a European Union’s Horizon 2020 Research and Innovation Programme SME (Small and Medium sized Enterprises) instrument for phase 1. This will help OnDosis progress the work in developing its product for ADHD. Supporting its connectivity interface OnDosis has also been contracted by a EUREKA cluster 5G project.

Shaping the journey of a new life science company?

After two successful years since being founded, OnDosis is accelerating. We are now looking for a Co-Pilot to the CEO, a position which will be critical in order to drive the company towards our ambition. We are looking for an energetic doer. A person that is making things happen, connecting dots and building relationships. This individual will grow with OnDosis and be part of a small but dynamic leadership team. Is it you?

OnDosis has been chosen as one of the companies selected to the Swedish IVA 100 list

The IVA (Royal Swedish Academy of Engineering Sciences) is an independent academy whose mission is “...to promote the engineering and economic sciences and the advancement of business and industry for the benefit of society”. IVA’s list brings together research that can form the basis of innovation in the form of new companies, new products and services, business development or other form of benefit.

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

Swedish life science company, OnDosis, and global contract development and manufacturing organisation (CDMO), Recipharm, have entered into an agreement for the formulation development of an ADHD treatment for the US market.

Introducing OnDosis, a new life science company

Based on innovative technology developed by AstraZeneca, OnDosis is a new, Gothenburg-based, life science company with the mission to simplify dosing and enable personalised administration of medicines by connecting medicines, devices and digital health to benefit patients. AstraZeneca and GU Ventures have founded OnDosis together with entrepreneurial CEO, Martin Olovsson.